News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Patrys.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Kick Podcast: Can listed Aussie drug makers survive COVID-19?
Health & Biotech
Health: Patrys gets a bounce after a promising pre-clinical trial for metastatic cancer treatment
Health & Biotech
Here’s how to pick a successful drug out of the 99pc of failures
Health & Biotech
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
Health & Biotech
Health: ResApp popping bottles in the ice as cough app finally gets approval; shares fly
Health & Biotech
Dr Boreham’s Crucible: ‘Robust’ biotech and Kerry Stokes as a backer, so what’s holding down Patrys’ share price?
Health & Biotech
Biotech: Patrys is up 41pc after getting very good at curing brain cancer – in mice
News
Tl;dr? Here are your Budget cliff notes on what’s in store for ASX small caps
Health & Biotech
‘Mice are a failed experiment’: Why you shouldn’t get revved up about pre-clinical trials
Health & Biotech
8 biotechs that either flew or sunk on clinical trial results in 2018
Health & Biotech
Fliers, flameouts and fakers: what happened in biotechland in 2018
News
Lunchtime ASX small cap wrap: who’s still got a job for Christmas
Health & Biotech
Patrys’ cancer drug worked wonders in mice with breast cancer
Health & Biotech
Trying to pick the next Biotron or BARD1? Here’s what you need to know
Health & Biotech
It’s breast cancer awareness month – here are 10 ASX biotechs tackling the disease
Health & Biotech
Patrys continues brain cancer drug trials – and is also chasing an insurance claim over bung antibodies
Health & Biotech